Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Research area

Phase 3 Lymphoma trials

The lymphoma studies listed here are all in Phase 3, including combined Phase 2/3. If you want to know whether one may fit you, Phase 3 Cancer Trials can help you find out.

Updated

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Phase 3 lymphoma studies in numbers

Phase 3 lymphoma studies recruiting in the U.S.
49
states with a study site
50
studies that accept healthy volunteers
1

Source: ClinicalTrials.gov. Data processed .

Find Phase 3 lymphoma studies by state

These states have the most studies recruiting right now.

Phase 3 lymphoma studies recruiting now

As of November 18, 2026, 49 Phase 3 lymphoma studies are recruiting participants in the United States, according to ClinicalTrials.gov. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry. This is what they have in common.

What they test

  • medications43
  • biologics such as vaccines or antibodies16
  • other approaches12
  • procedures12
  • radiation6

A study can test more than one.

Main purpose

  • treating a condition47
  • supportive care2

Phase

  • Phase 2/33
  • Phase 346

Who runs them

  • industry32
  • university, hospital or other13
  • government4

Who they enroll

  • adults (18 to 64)48
  • older adults (65 and over)45
  • mainly children and teens (under 18)1

1 also accept healthy volunteers.

These counts come from each study's public record and change as studies open and close. Browse every location to see what is recruiting near you.

Source: ClinicalTrials.gov. Data processed . Each bar shows a count as a share of all 49 studies.

Recently updated Phase 3 lymphoma studies

The 6 studies whose public records changed most recently, with some of the places each is recruiting. Select a study to read its full record on ClinicalTrials.gov.

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ames, IA · Anaconda, MT · Ankeny, IA · and 210 more U.S. locations
    Registry record
    NCT06337318 · updated
  2. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Recruiting in
    Atlanta, GA · Aurora, CO · Billings, MT · and 38 more U.S. locations
    Registry record
    NCT05303519 · updated
  3. A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Aberdeen, SD · Albany, NY · Bethesda, MD · and 21 more U.S. locations
    Registry record
    NCT05947851 · updated
  4. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Albany, NY · Austin, TX · Billings, MT · and 41 more U.S. locations
    Registry record
    NCT06136559 · updated
  5. ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Newave Pharmaceutical Inc
    Recruiting in
    Bethesda, MD · Durham, NC · Las Vegas, NV · and 3 more U.S. locations
    Registry record
    NCT07342478 · updated
  6. Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Chicago, IL
    Registry record
    NCT07724457 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in the United States on ClinicalTrials.gov.

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and some of the places it is recruiting) exactly as registered. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

What Phase 3 lymphoma studies look at

The lymphoma studies listed here are all in Phase 3, counting combined Phase 2/3. One specific question sits behind each of them. So the things you would be asked to do change from one Phase 3 study to the next.

In every one of these lymphoma studies, the thing under test is investigational. Researchers do not yet have a full picture of how it performs or what risks it carries. Closing that gap is the reason each Phase 3 study is run.

Who may be able to take part

No two Phase 3 lymphoma studies ask for exactly the same things. A study may look at your age and your health history. It may also look at the medications you take now and the way lymphoma affects you. Some Phase 3 studies take people without lymphoma as well.

You are not expected to judge your own fit. The study team does that checking when you come in for screening. Our guide to eligibility and screening explains the process.

What taking part usually involves

  1. A first conversation

    Your first conversation is with a coordinator, who outlines the Phase 3 lymphoma study in general terms. The questions you bring are answered at that point, ahead of any other step.

  2. Informed consent

    A written document from the study team sets out everything about the Phase 3 study. The risks known so far are included. Agreeing or not is your decision.

  3. Screening

    The team asks about your health and runs tests to see if this Phase 3 study is a suitable fit. Screening does not always lead to taking part.

  4. Study visits

    Once you are in a Phase 3 study, visits are set on a schedule. They let the team keep watch on your health. You are free to withdraw whenever you choose.

Questions about Phase 3 lymphoma studies

Do I need a diagnosis to join a study about lymphoma?

That varies from one Phase 3 lymphoma study to the next. A confirmed diagnosis is asked for by some. Others assess you while screening is under way. Which of the two applies to you is for the study team to explain.

Would I have to change the care I receive now?

It varies by study, and altering any care alone is not the way to handle it. Current care carries on in some Phase 3 lymphoma studies. In others it cannot. Expect the study doctor to go over this point with you. Ahead of any decision, your own doctor is someone to talk it through with as well.

Is there a cost to take part?

As a rule, participants in a Phase 3 study are not charged for its visits, its tests or the medication being studied. Our costs page has more detail.

Ask about Phase 3 lymphoma studies

Give us some basic details. A coordinator will then reach out. Asking about a Phase 3 lymphoma study leaves you free of any commitment.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Independent information

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call